PC
TGTX icon

Pier Capital’s TG Therapeutics TGTX Stock Holding History

Pier Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-392,709
Closed -$3.28M – 136
2023
Q3 		$3.28M Buy
392,709
+158,391
+68% +$2.21M 0.53% 84
2023
Q2 		$5.82M Buy
234,318
+846
+0.4% +$21.9K 0.84% 64
2023
Q1 		$3.51M Buy
+233,472
New +$3.55M 0.53% 90
2021
Q3 		– Sell
-280,486
Closed -$10.9M – 122
2021
Q2 		$10.9M Buy
280,486
+27,215
+11% +$1.07M 1.09% 45
2021
Q1 		$12.2M Buy
253,271
+108,857
+75% +$5.23M 1.16% 33
2020
Q4 		$7.51M Sell
144,414
-124,390
-46% -$4.2M 0.8% 80
2020
Q3 		$7.19M Buy
+268,804
New +$6.19M 1.05% 51

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Pier Capital's TGTX Position: Q4 2023 in Review

Pier Capital sold out of TG Therapeutics (TGTX) in Q4 2023, closing a stake of 392,709 shares — an estimated $3.28M sold.

Pier Capital first reported a position in TGTX in Q3 2020 and held it in 7 quarters. The position peaked at $12.2M in Q1 2021. 235 funds tracked by Wall St. Rank hold TGTX as of Q4 2023.

  • Pier Capital reported no remaining TG Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Pier Capital sold 392,709 TG Therapeutics shares in Q4 2023, an estimated $3.28M.
  • Pier Capital first reported a position in TG Therapeutics in Q3 2020 and held it in 7 quarters.
  • Pier Capital's TG Therapeutics position peaked at $12.2M in Q1 2021.
  • 235 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2023.

Based on Pier Capital's 13F filing for Q4 2023, filed 15 Feb 2024.